Online inquiry

IVTScrip™ pSP6-VEE-mRNA-Anti-CD37, 177lu-DOTA-HH1 Vector   (CAT#: GTVCR-WQ57MR)

This product GTVCR-WQ57MR is an effective transcription system suitable for a variety of research, including the in vitro translation, self-amplifying mRNA studies and protein expression. The system was driven by the SP6 promoter to efficiently generate mRNA ecoding antibody which targeting CD37. The vector contains the self-replicating Venezuelan equine encephalitis (VEE) virus RNA replicon, which resulting the mRNA expression at a high level.

SPECIFIC INQUIRY

3' poly(A):
Inquiry
Specifications
Product type Vector
Promoter SP6
Resistance Ampicillin
Species Mus musculus
RefSeq NM_001040031.2
Applications IVT; Self-amplifying mRNA (SAM) research; Gene therapy research
Format Solution
Concentration 1 µg/µl
Quantity 10 µg
Target Gene
Gene ID 951
UniProt ID P11049
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ pSP6-VEE-mRNA-Anti-CD37, 177lu-DOTA-HH1 Vector (GTVCR-WQ57MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTVCR-WQ2490MR IVTScrip™ pSP6-VEE-mRNA-Anti-SLC39A6, SGN-LIV1A Vector Vector SGN-LIV1A
GTVCR-WQ347MR IVTScrip™ pT7-VEE-mRNA-Anti-CD274, AHLX-20 Vector Vector AHLX-20
GTVCR-WQ1783MR IVTScrip™ pT7-VEE-mRNA-Anti-S, LY-3819253 Vector Vector LY-3819253
GTVCR-WQ1832MR IVTScrip™ pT7-VEE-mRNA-Anti-HAVCR2, MBG-453 Vector Vector MBG-453
GTVCR-WQ1179MR IVTScrip™ pT7-VEE-mRNA-Anti-EGFR, Fab C225 Vector Vector Fab C225
GTVCR-WQ369MR IVTScrip™ pSP6-VEE-mRNA-Anti-IL6, ALD-518 Vector Vector ALD-518
GTVCR-WQ169MR IVTScrip™ pSP6-VEE-mRNA-Anti-CD40, ABBV-323 Vector Vector ABBV-323
GTVCR-WQ87MR IVTScrip™ pT7-VEE-mRNA-Anti-SELP, 42-89-glycoprotein Vector Vector 42-89-glycoprotein
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW